H17-pseudotyped viruses. We identified the human HLA-DR receptor as an entry mediator for H17 pseudotypes, suggesting that H17N10 possesses zoonotic potential.
). Madin-Darby canine kidney (MDCK) II (unlike MDCK I) cells are susceptible to H17-PV ( Fig. 1c ) in agreement with previous studies 10, 11 . MDCK II cells were not susceptible to PV expressing N10 alone, while particles bearing H17 alone or both H17 and N10 transduced these cells with high, comparable efficiency, indicating that N10 is dispensable for entry, in keeping with published data 9, 11 . To characterize the H17 putative receptor(s), MDCK II cells were (pre-)treated with enzymatic agents before transduction ( Fig. 1d ). Pre-treatment with neuraminidase, which cleaves surface sialic acid, reduced transduction by H5-PV (by 68-86%) but not by H17-PV, further supporting the notion that sialic acid is not the H17 receptor [8] [9] [10] [11] .
IAVs primarily enter cells via endocytosis followed by low pHtriggered endosomal fusion. Treatment of cells with ammonium chloride blocked uptake of H5-PV and H17-PV, demonstrating that entry of H17, like IAVs, is pH dependent consistent with a previous study 9 . Entry of H17-PV was more affected than H5-PV by pretreatment of cells with proteases or an inhibitor of N-glycosylation (reduced by up to 72% and 78%, compared with 45% and 20%, respectively), supporting the supposition 9 that the H17-receptor(s) is a glycoprotein.
MDCK cells are heterogeneous, displaying phenotypic variation 14 , with MDCK I and MDCK II representing early and late passages of the parental NBL-2 cells. Transcriptional differences between early (passage 8) and late (passage 21) MDCK cells were investigated using microarrays, identifying 17 differentially regulated transcripts ( Fig. 2a ). Using transmembrane domain and subcellular localization prediction algorithms, we identified the dog leukocyte antigen DRα-chain (DLA-DRA) as the only transcript encoding a surface-anchored protein, over-expressed in late, compared with early, passage cells (Supplementary Table 2 ). Significant over-expression of DLA-DRA (and the paralogue DLA-DRB1) was confirmed by quantitative PCR with reverse transcription (RT-qPCR) in MDCK II cells compared with MDCK I cells (Fig. 2b) .
DLA-DRA is a well-conserved orthologue of the human MHC class II HLA-DRA ( Supplementary Fig. 1 ). MHC class II molecules are heterodimers of two glycosylated, transmembrane polypeptide chains (monomorphic-α and polymorphic-β), expressed selectively on antigen-presenting cells (Fig. 2c ). HLA-DR forms complexes with endocytosed foreign peptides, which are presented to CD4 + T helper cells for recognition 15 . To assess the zoonotic potential of H17N10, we explored the H17-PV tropism using human cell lines with known elevated HLA-DR expression levels 15 (Fig. 2d ). Burkitt's lymphoma-derived Raji, Ramos and BJAB B lymphocytes and the B lymphoblastoid cells (B-LCL) show decreasing susceptibility, in that order, to H17-PV. Kasumi-1 leukaemic cells showed marginal susceptibility, whereas Molt-4 and HL-60 leukaemic cells, Jurkat T cells, pro-monocytic THP-1 and U-937 cells and primary B cells showed no susceptibility to H17-PV. Differential susceptibility to H17-PV correlated with HLA-DRA expression levels (confirmed by RT-qPCR). Surface expression of the heterodimer was assayed by flow cytometry 16 ( Fig. 2e ) and showed an association with susceptibility to H17-PV.
Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II
We investigated whether ectopic expression of HLA-DR was sufficient to render non-antigen-presenting cells susceptible to H17-PV. HEK293T/17 cells were transiently co-transfected with the DRA and DRB1 expression vectors. Surface expression of the heterodimer was confirmed via immunofluorescence ( Supplementary Fig. 2 ). Flow cytometry confirmed that 47% of cells formed a functional surface heterodimer ( Fig. 2f ). Over-expression of HLA-DR resulted in significant transduction by H17-PV. Furthermore, transduction was enhanced twofold (Fig. 2g ) in cells enriched for HLA-DR by fluorescence-activated cell sorting (FACS). Similar results were obtained using bat cells ( Supplementary Fig. 3 ). Conversely, small interfering RNA (siRNA) targeting HLA-DRA ( Fig. 2h ) or MHC class II monoclonal antibodies (mAbs) ( Fig. 2i and Supplementary  Fig. 4 ) drastically reduced the susceptibility of Raji cells to H17-PV.
Together, these findings demonstrate HLA-DR functions as a bona fide entry mediator for H17N10. Similarly, Karakus et al. determined that bat, pig, mouse or chicken HLA-DR orthologues mediate cell entry of H18N11 (ref. 17 ). Through efficient binding to HLA-DR, BatIVs might simultaneously access antigen-presenting cells and block T cell responses. This might explain the viruses' survival and asymptomatic status in carrier bats.
With limited functional information available on bat MHC class II, its role in the pathogenesis and transmission of BatIVs remains obscure. Nevertheless, the observation that H17N10 can enter human HLA-DR + cells implies that the virus has zoonotic potential.
Methods
Cell culture and treatment. Cell lines are described in Supplementary Table 1 and were cultured according to standard protocols (www.atcc.org). Bat cell lines were propagated in DMEM supplemented with heat-inactivated 15% FBS (Life Technologies), penicillin (100 U ml −1 ) and streptomycin (100 μg ml −1 ; Invitrogen) and maintained at 37 °C and 5% CO 2 .
MDCK II cells were treated as previously described 9 with either the endosomal acidification reagent ammonium chloride (1-100 mM) or pre-treated with neuraminidase from Clostridium perfrigens for 2 h (1-100 mM), or pronase for 30 min (endoproteases and exoproteases from Streptomyces griseus at 5-50 μg ml −1 ; Calbiochem) or an N-glycosylation inhibitor for 5 h (tunicamycin at 0.01-1 μg ml −1 ; Sigma-Aldrich). For experiments using glycosidases, Raji and Ramos cells were treated as previously described 18 with 0-100 U ml −1 peptide:N-glycosidase F (Calbiochem) or endoglycosidase H (New England Biolabs) or a mixture of neuraminidase (50 mM) and O-glycosidase (1-20 mU ml −1 ) in HBSS (Sigma) for 2 h at 37 °C. Cells were washed twice with HBSS and transduced with H17-PV and VSV-G-PV for 2 h. The cells were then resuspended in fresh growth medium for 24-48 h before assay. Bafilomycin A1 (Calbiochem) was used at a concentration of 10 nM. Cell viabilities were assessed by a trypan blue exclusion test.
Pseudotype production and susceptibility assays. Pseudotypes expressing H17 and N10 (from A/little yellow-shouldered bat/Guatemala/060/2011), H5 (A/Vietnam/1194/2004; H5N1 clade 1) or VSV (vesicular stomatitis virus)-G glycoproteins were produced as described 13 . Briefly, the lentiviral packaging plasmid p8.91, the pCSFLW firefly luciferase vector, the pI.18 expression plasmids for H17 and/or N10 and the protease encoding plasmid pCAGGS-human airway trypsin-like protease were co-transfected using polyethylenimine reagent (Sigma-Aldrich) into HEK293T/17 cells. Filtered supernatants were collected 48-72 h post-transfection. To remove viral titre bias between different stocks, PVs were concentrated and (re-) titrated by serial dilution. Concentration was carried out by ultra-centrifugation for 2 h at 25,000 r.p.m. at 4 °C (Beckman Optima XL-100 K Ultracentrifuge). Twofold serial dilutions of PV-containing supernatant were performed as previously described 13 using 96-well plates. Subsequently, 1 × 10 4 (for adherent) and 3 × 10 4 (for suspension) cells were added in 50 µl medium per well. Plates were incubated for 24-48 h, after which 50 µl Bright-Glo substrate (Promega) was added. Luciferase readings were conducted with a luminometer (FLUOstar OPTIMA, BMG Labtech) after a 5-min incubation. Data were normalized using Δ-env and cell-only measurements and expressed as relative luminescence units (RLU) per ml.
Plasmids and transfections.
Expression plasmids for HLA-DRA (NM_019111) and HLA-DRB1 (NM_001243965) were purchased from GenScript. HEK293T/17 at subconfluence in 6-well plates or 100-mm dishes were transfected with HLA-DRA or HLA-DRB1 plasmids or a 1/1 combination of both using Lipofectamine 3000 (Thermo Fisher). Forty-eight hours after transfection, cells were used either for immunofluorescence analysis, for FACS analysis or for PV transduction. The transfection efficiency, as assessed by the green fluorescent protein expression of a control plasmid, was >70% under microscopic observation. PakiTO3 cells were transfected with HLA-DR plasmids and selected with geneticin (500 μg ml −1 ). . RT-qPCR significance was calculated by two-sided t-test (P = 0.0065). i, The percentage H17-and VSV-G-PV transduction levels (means ± s.d., n = 3) in Raji cells pre-incubated with MHC class II mAb are shown in blue and red, respectively. Significance of H17-PV transduction reduction was calculated by one-way ANOVA and Dunnett's tests (***P = 0.0003 for 1 μg ml -1 and ****P < 0.0001 for 10 and 20 μg ml -1 mAb).
Microarray analysis. Total RNA was isolated from triplicates of early-passaged and late passaged MDCK cells using a Ribopure kit (Ambion). Preparation of samples and hybridization to Affymetrix Canine Genome 2.0 GeneChips were performed according to standard Affymetrix protocols. A one-way analysis of variance (ANOVA) adjusted with the Benjamini-Hochberg multiple-testing correction (P < 0.05) was performed with Partek Genomics Suite (v6.6) as previously described 19 .
HLA-DRA knockdown and blocking using siRNA and mAbs. A Sigma-Aldrich MISSION endonuclease-derived esiRNA (EHU226621) was used to knockdown HLA-DRA expression in Raji cells. Lipofectamine RNAiMAX reagent (Thermo Fisher) was used to transfect exponentially grown cells with 50 nM siHLA-DRA or siControl (SIC001). Initial transfection was followed by re-transfection of cells on the following day. Cells were collected after 48 h and either seeded for transduction with PV or processed to validate siRNA activity (by RT-qPCR and western blot).
To evaluate the interaction of HLA-DR with H17, we used the broadly reactive MHC class II mAb WR18 (code MCA477, Bio-Rad) and anti-HLA-DR mAb (clone 302CT2, Enzo Life Sciences). After 1 h of pre-incubation with increasing mAb concentrations of the antibody, Raji cells (3 × 10 4 ) were transduced for 2 h with H17-PV or VSV-G-PV. The cells were then resuspended in fresh growth medium and luciferase was measured after 24 h.
Western blot analysis.
Washed cells were lysed on ice with lysis buffer (0.5% NP-40 in PBS with 10 mM Tris-HCl, pH 7.4, supplemented with protease inhibitors (Thermo Fisher)) and protein was quantified by the BCA assay kit (Thermo Fisher). Of the protein, 20-50 μg was electrophoresed on a 4-15% sodium dodecylsulfate polyacrylamide gel, alongside a protein ladder (Bio-Rad) and immunoblotted with the mouse mAb anti-HLA-DRA (1:1,000; clone: 302CT2, Enzo Life Sciences) or rabbit mAb α-tubulin (1:2,000; Cell Signaling Technology). The membranes were washed and incubated with goat anti-rabbit or donkey antimouse secondary antibodies (LI-COR) in the dark for 1 h. Scanning was carried out using the Odyssey Imaging System.
Immunofluorescence. Transfected cells were seeded onto glass cover slips overnight and were fixed with 4% paraformaldehyde. Fixed cells were then washed and permeabilized with 1% Triton X-100 in PBS for 10 min. After washing, the cover slips were incubated with a mouse HLA-DRA mAb (169-1B5.2, Bio-Techne) targeting a monomorphic HLA-DR framework determinant for 1 h, washed and incubated with anti-mouse Alexa Fluor-488-conjugated antibody (Thermo Fisher) for 30 min. Cover slips were mounted using Prolong Gold containing DAPI (Invitrogen). Images were acquired on an EVOS fluorescent microscope (Life Technology). Experiments were carried out in duplicate.
Flow cytometry. For surface staining, cells were washed twice in ice-cold FACS buffer and stained with a fluorescein isothiocyanate (FITC)-conjugated antihuman HLA-DR mAb (clone Tü36, BDIS), which binds to a monomorphic epitope of the αβ complex and not the isolated α or β chains or the HLA-DP and HLA-DQ isotypes 16 . The BD LSR Fortressa was used to determine the expression of HLA-DR, in combination with the matched isotype control, and cells were sorted into HLA-DR − and HLA-DR + subpopulations with a FACS Aria cell sorter (BDIS). The Hoechst 33342 stain was used for cell viability discrimination, and the data files were analysed using FlowJo software v10.0 (Tree Star, Inc.). Experiments were carried out in duplicate. For the gating strategy, cells were first identified by forward (FSC-Area) versus side (SSC-Area) scatter gating based on cell size and granularity, then the FSC-Area versus FSC-Height gating for single cells. Dead cells were excluded by gating on Hoechst 33342-negative cells. Positive and negative gates for HLA-DR expression were determined by using isotype and unstained controls.
RT-qPCR analysis. RT-qPCR was performed using procedures described previously 19 . RT-qPCR was conducted in a 384-well plate with the ABI-7900HT system (Applied Biosystems). The following primers were used: DLA-DRA (forward: 5′-GCTGTGGACAAAGCTAACCTTG-3′, reverse: 5′-TCTGGAGGT ACATTGGTGTTCG-3′), DLA-DRB1 (forward: 5′-AGCACCAAGTTTGACAA GC-3′, reverse: 5-AAGAGCAGACCCAGGACAAAG-3′). Absolute copy numbers of HLA-DRA were calculated using a standard curve of known concentrations of the corresponding expression plasmid. HLA-DRA (forward: 5′-TCAAGGGATT GCGCAAAAGC-3′, reverse: 5′-ACACCATCACCTCCATGTGC-3′).
Bioinformatic and statistical analyses. Phobius 20 and TMHMM v2.0 (ref. 21 ) software were used to predict the existence of transmembrane domains, and Deeploc-1.0 (ref. 22 ) was used to determine subcellular protein localization. The amino acid sequences of DLA-DRA (NP_001011723.1), HLA-DRA (NP_061984.2) and their bat orthologues ((Pteropus alecto (XP_006907484.1); Desmodus rotundus (XP_024413747.1)) were subjected to multiple alignment using CLC workbench 7. Graphical representation and statistical analyses were performed using Prism 8 (GraphPad). Unless otherwise stated, results are shown as means ± s.e.m. from three independent experiments. Selection of statistical analysis was based on the data distribution. Data distributions were tested for normality using the Shapiro-Wilk normality test. P < 0.05 was considered significant unless otherwise stated.
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Data availability
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Sample size
A high number of primary and immortalised cell lines (>40) was used covering different species (humans, chicken, dog, pig, bats, hamster, mouse) and tissues (epithelial/endothelial) to assess the distribution of the H17 putative receptors. All experiments were performed with at least three independent biological replicates unless otherwise stated. Each value shown in figures was presented as the mean value of the biological replicates, with standard error or standard deviation shown as error bars. p-values were not always presented in the study, since our data sought qualitative differences in luciferase assays, microscopic images and flow cytometry profiles.
Data exclusions No data were excluded from the analyses Replication All attempts at replication were succesful Randomization Randomisation was not used
Blinding
No blinding was carried out, since experiments did not involve animals or human subjects. Furthermore, cell cultures used in this study have different growth requirements, which makes blinding complicated and unnecessary.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials

Validation
We used well-validated commercial antibody reagents for western blot, immunofluorescence and flow cytometry. Validation data are available on the manufacturer's websites and data sheets: Briefly, Clone Tü36 binds to a monomorphic epitope of the HLA-DR αβ complex and not the isolated α or β chains or the HLA-DP and -DQ isotypes. Clone 302CT2.3.2 is generated from mice immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from human HLA-DRA. Clone 169-1B5.2 targets a monomorphic HLA-DR framework determinant and does not cross-react with HLA-DP and HLA-DQ. Clone WR18 reacts with a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
Sources (vendors and catalogue numbers) of individual cell lines are described in detail in supplementary table 1.
